Home

Team

Project

Parts

Protocol

Notebook

Results

Safety

Human Practice

Safety

Before answering these questions on your team Safety page, be sure to read the Safety in iGEM page. and the FAQ section below.

Basic Safety Questions for iGEM 2013

a. Please describe the chassis organism(s) you will be using for this project. If you will be using more than one chassis organism, provide information on each of them:

*For additional organisms, please include a spreadsheet in your submission.

2. Highest Risk Group Listed:

　　1　●　　　　　　　Greater than 1　○

If you answered 1+, please also complete the iGEM Biosafety form part 2 for any organisms in this category.

3. List and describe all new or modified coding regions you will be using in your project.
(If you use parts from the 2013　iGEM Distribution without modifying them, you do not need to list those parts.)

*For additional coding regions, please include a spreadsheet in your submission.

4. Do the biological materials used in your lab work pose any of the following risks? Please describe.

a. Risks to the safety and health of team members or others working in the lab?

We used E.coli Pro 5-alpha. It doesn’t cause irritation effect on the skin. And it doesn't sensitize us.

b. Risks to the safety and health of the general public, if released by design or by accident?

We used E.coli Pro 5-alpha. It doesn’t cause irritation effect on the skin. And it doesn't sensitize us.

c. Risks to the environment, if released by design or by accident?

Aquatic toxicity: Not harmful to the aquatic environment.

d. Risks to security through malicious misuse by individuals, groups, or countries?

We discard the experimental dust after autoclave. Therefore there cannot be the thing leaking outside.

5. If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise?(Consider the different categories of risks that are listed in parts a-d of the previous question.)
Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?
(Note: This is meant to be a somewhat open-ended discussion question.)

• It may fall into autoimmune disease by Th1 increasing excessively.

• α-hemolysin (Used as a tag to start it outside IL-12) provides hemolysis.

• When a human being took E coli, it is concerned whether you are safe.

6. Does your project include any design features to address safety risks?
(For example: kill switches, auxotrophic chassis, etc.)
Note that including such features is not mandatory to participate in iGEM, but many groups choose to include them.

[PDF]